Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD), W Hohenberger, T Iveson, J Karner, J Levi, T Hugh, J De Greve, A Chan, B Davidson, P Lindnér, M Peeters, B Stein, T Diamond, M Ducreux, P Lasser, U Graeven, B Paillot, J Doran, C Gouillat, I Iesalnieks, K W Jauch, P Jagot-Lacoussiere, R L Jansen, H Koehne, R Konopke, F Otto, D Sherlock, G Van Hazel, S Ackland, L Bedenne, E Bories, M C Clavero-Fabri, T Conroy, M C Kaminsky-Forrett, F Husseini, C Karapetis, L Müller, T Price, R Rosenberg, J Schott, J Tschmelitsch, J L Van Laethem, J Wals, A Weimann, J P Arnaud, D Arsene, D Auby, S Bhattacharya, E Cebon, D Cherqui, C Confente, B Dousset, N Frickhofen, A Frilling, P Evan, V Ganju, K Höffken, F Lazorthes, C Letoublon, A Madroszyk, D Nitti, B Orr, E A Pariente, J C Pector, J L Raoul, M Rees, K Ridwelski, P Rouanet, G J Toogood, P Vergauwe, H J Wilke, Richard Kaplan, Jean-Claude Horiot, Bo Littbrand, Ahmad Awada, Sally Stenning, Ferdy Lejeune, Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD), W Hohenberger, T Iveson, J Karner, J Levi, T Hugh, J De Greve, A Chan, B Davidson, P Lindnér, M Peeters, B Stein, T Diamond, M Ducreux, P Lasser, U Graeven, B Paillot, J Doran, C Gouillat, I Iesalnieks, K W Jauch, P Jagot-Lacoussiere, R L Jansen, H Koehne, R Konopke, F Otto, D Sherlock, G Van Hazel, S Ackland, L Bedenne, E Bories, M C Clavero-Fabri, T Conroy, M C Kaminsky-Forrett, F Husseini, C Karapetis, L Müller, T Price, R Rosenberg, J Schott, J Tschmelitsch, J L Van Laethem, J Wals, A Weimann, J P Arnaud, D Arsene, D Auby, S Bhattacharya, E Cebon, D Cherqui, C Confente, B Dousset, N Frickhofen, A Frilling, P Evan, V Ganju, K Höffken, F Lazorthes, C Letoublon, A Madroszyk, D Nitti, B Orr, E A Pariente, J C Pector, J L Raoul, M Rees, K Ridwelski, P Rouanet, G J Toogood, P Vergauwe, H J Wilke, Richard Kaplan, Jean-Claude Horiot, Bo Littbrand, Ahmad Awada, Sally Stenning, Ferdy Lejeune

Abstract

Background: Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer.

Methods: This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0.71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479.

Findings: In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1-6) preoperative cycles and 115 (63%) patients received a median six (1-8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7.3% (from 28.1% [95.66% CI 21.3-35.5] to 35.4% [28.1-42.7]; HR 0.79 [0.62-1.02]; p=0.058) in randomised patients; 8.1% (from 28.1% [21.2-36.6] to 36.2% [28.7-43.8]; HR 0.77 [0.60-1.00]; p=0.041) in eligible patients; and 9.2% (from 33.2% [25.3-41.2] to 42.4% [34.0-50.5]; HR 0.73 [0.55-0.97]; p=0.025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0.04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group.

Interpretation: Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients.

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Progression-free survival by treatment group (A) All randomly assigned patients. (B) All eligible patients. (C) All resected patients. For all patients randomly assigned and those who were eligible, no surgery or no resection were regarded as events for the primary endpoint of progression-free survival. PeriOpCT=perioperative chemotherapy with fluorouracil or leucovorin, and oxaliplatin.

References

    1. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318.
    1. Nordlinger B, Guiguet M, Vaillant J-C. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–1262.
    1. Giacchetti S, Itzhaki M, Gruia G. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10:663–669.
    1. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351.
    1. Lorenz M, Muller HH, Schramm H. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen) Ann Surg. 1998;228:756–762.
    1. Kemeny N, Huang Y, Cohen AM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048.
    1. Kemeny MM, Adak S, Gray B. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol. 2002;20:1499–1505.
    1. Mitry E, Fields A, Bleiberg H. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24:152s.
    1. Portier G, Elias D, Bouche O. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–4982.
    1. National Cancer Institute Common toxicity criteria version 2.0. April 30, 1999. (accessed July 30, 2007).
    1. Freedman LS, White SJ. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics. 1976;32:691–694.
    1. de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
    1. Cunningham D, Allum WH, Stenning SP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
    1. Therasse P, Arbuck SG, Eisenhauer E. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216.
    1. Hwang IK, Shih WJ, DeCani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med. 1990;9:1439–1445.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
    1. Kalbfleisch JD, Prentice RL. Statistical analysis of failure time data. Wiley; New York: 1980. pp. 163–178.
    1. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003;238:871–883.
    1. Kokudo N, Hasegawa K, Makuuchi M. Control arm for surgery alone is needed but difficult to obtain in randomized trials for adjuvant chemotherapy after liver resection for colorectal metastases. J Clin Oncol. 2007;25:1299–1300.
    1. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–1268.
    1. Adam R, Pascal G, Castaing D. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–1061.
    1. Rubbia-Brandt L, Audard V, Sartoretti P. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.
    1. Bilchik AJ, Poston G, Curley SA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol. 2005;23:9073–9078.
    1. Vauthey JN, Pawlik TM, Ribero D. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072.
    1. Karoui M, Penna C, Amin-Hashem M. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.
    1. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597–608.
    1. Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
    1. Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.
    1. Hoff PM, Ellis LM. Targeted therapy trials: approval strategies, target validation, or helping patients? J Clin Oncol. 2007;1:1639–1641.
    1. National Cancer Institute EORTC protocol 40051 BOS: randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. (accessed July 30, 2007).

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅